Indie Asset Partners’s ADC Therapeutics ADCT Stock Holding History

Indie Asset Partners’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-92,700	Closed	-$154K	–	87
2023 Q4	$154K	Hold	92,700	–	–	0.14%	80
2023 Q3	$83.2K	Sell	92,700 -1,139	-1%	-$1.51K	0.08%	74
2023 Q2	$202K	Hold	93,839	–	–	0.22%	76
2023 Q1	$183K	Hold	93,839	–	–	0.21%	81
2022 Q4	$360K	Hold	93,839	–	–	0.39%	49
2022 Q3	$452K	Sell	93,839 -150	-0.2%	-$1.09K	0.46%	39
2022 Q2	$747K	Sell	93,989 -2,583	-3%	-$24.4K	0.66%	26
2022 Q1	$1.42M	Sell	96,572 -10	-0%	-$159	1.07%	13
2021 Q4	$1.95M	Sell	96,582 -829	-0.9%	-$20K	1.42%	10
2021 Q3	$2.65M	Buy	97,411 +5,770	+6%	+$148K	2.14%	7
2021 Q2	$2.23M	Sell	91,641 -475	-0.5%	-$11K	1.81%	8
2021 Q1	$2.25M	Sell	92,116 -171	-0.2%	-$4.95K	2.56%	6
2020 Q4	$2.95M	Buy	+92,287	New	+$3.02M	3.44%	5

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Indie Asset Partners's ADCT Position: Q1 2024 in Review

Indie Asset Partners sold out of ADC Therapeutics (ADCT) in Q1 2024, closing a stake of 92,700 shares — an estimated $154K sold.

Indie Asset Partners first reported a position in ADCT in Q4 2020 and held it in 13 quarters. The position peaked at $2.95M in Q4 2020. 36 funds tracked by Wall St. Rank hold ADCT as of Q1 2024.

Indie Asset Partners reported no remaining ADC Therapeutics position as of Q1 2024 after selling out during the quarter.
Indie Asset Partners sold 92,700 ADC Therapeutics shares in Q1 2024, an estimated $154K.
Indie Asset Partners first reported a position in ADC Therapeutics in Q4 2020 and held it in 13 quarters.
Indie Asset Partners's ADC Therapeutics position peaked at $2.95M in Q4 2020.
36 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2024.

Based on Indie Asset Partners's 13F filing for Q1 2024, filed 10 May 2024.